Biotech RadarJobs updated

COMPANY

Guardant Health

guardanthealth.com ↗ · West Coast

FDA-cleared device company

Keywords: oncology Non-small Cell Lung Cancer Colorectal Cancer Colo-rectal Cancer Bladder Carcinoma Ureter Carcinoma Renal Pelvis Carcinoma Invasive Breast Carcinoma Cutaneous Melanoma Esophageal Carcinoma Gastroesophageal Junction Carcinoma Gastric Adenocarcinoma Pancreatic Adenocarcinoma Squamous Cell Carcinoma of the Head and Neck Epithelial Ovarian Carcinoma Fallopian Tube Carcinoma Endometrial Carcinoma Renal Cell Carcinoma Rectal Adenocarcinoma Colon Adenocarcinoma Breast Cancer Lung Cancer Advanced Breast Cancer Non-Hematologic Malignancy Non-small Cell Lung Cancer Metastatic

Profile checked Oct 10, 2026

$250.0MRaised (2 yrs)10Trials (company is sponsor)

Timeline

  1. Trial start —: Decision Counseling and Follow-up for Shield+ Patients source ↗
  2. Raise Follow-on offering: $250M (total, as published), announced Nov 5, 2025. Source: SEC filing. source ↗
  3. Debt Debt: $350M (not counted as a raise), announced Nov 5, 2025. Source: SEC filing. source ↗
  4. Trial start —: Shield Post-Approval Study Protocol source ↗
  5. Trial start —: SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation source ↗
  6. Trial start —: Screening for High Frequency Malignant Disease source ↗
  7. Trial start —: ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation source ↗
  8. Trial start —: Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer source ↗
  9. Trial start —: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode source ↗
  10. Trial start —: Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records source ↗
  11. Trial start —: Registry of Guardant360® Use and Outcomes In People With Advanced Cancer source ↗
  12. Trial start —: Noninvasive vs. Invasive Lung Evaluation source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $250.0M · Debt: $350.0M. Last 2 years.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT05059444ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNot listedRecruitingSep 7, 20212030-08 (estimated)
NCT05935384SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuationNot listedRecruitingOct 25, 2023Dec 30, 2030 (estimated)
NCT06880055Shield Post-Approval Study ProtocolNot listedRecruitingJul 14, 2025Sep 1, 2030 (estimated)
NCT05117840Screening for High Frequency Malignant DiseaseNot listedActive, not recruitingJan 13, 2022Dec 31, 2026 (estimated)
NCT07620535Decision Counseling and Follow-up for Shield+ PatientsNot listedNot yet recruiting2026-062027-12 (estimated)
NCT04136002Evaluation of the ctDNA LUNAR Test in an Average Patient Screening EpisodeNot listedActive, not recruitingOct 8, 2019Mar 20, 2024 (actual)
NCT04436393Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast CancerNot listedCompletedJul 2, 2020Mar 17, 2022 (actual)
NCT03615443Noninvasive vs. Invasive Lung EvaluationNot listedCompletedFeb 12, 2016Nov 23, 2020 (actual)
NCT03625557Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical RecordsNot listedCompletedApr 30, 2019Feb 1, 2020 (actual)
NCT03477474Registry of Guardant360® Use and Outcomes In People With Advanced CancerNot listedTerminatedApr 6, 2018Sep 1, 2019 (actual)

Connect

See your connections at Guardant Health on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback